As reported on MedCity News, the U.S. Food and Drug Administration has approved Takeda Pharmaceutical’s Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with
As reported on Drugs, BioNTech has decided to halt development of its Phase 2 BNT122-01 study investigating autogene cevumeran (BNT122/RO7198457) in patients with resected colorectal
As reported on PharmaBiz, BeOne Medicines has reported positive results from the second interim analysis of the phase 3 HERIZON-GEA-01 trial, further supporting the use
At 22, a young person’s world should be filled with possibilities—a career to build, places to travel, friendships to make, and a future to imagine.
As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has granted approval to PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) for the treatment of adults
In a recent press release, Novartis has reported positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials, showing that the investigational oral Bruton’s
As reported on Business Wire, the European Commission has approved trastuzumab deruxtecan (Enhertu) in combination with pertuzumab for the first-line treatment of adults with unresectable
As reported in the European Medical Journal, Novartis has paused eight clinical studies evaluating its experimental CAR-T cell therapy, known as rap-cell, after three trial
As reported in the European Medical Journal, new research suggests that cherry angiomas occur more frequently and at an earlier age in people with neurofibromatosis
In a recent press release, BioCryst Pharmaceuticals has shared that it received approval from Japan’s Ministry of Health, Labour and Welfare for the use of
As reported on Inside Precision Medicine, a new, non-invasive test may help doctors detect oral cancer quickly and reduce the need for painful scalpel biopsies.
Have you ever looked in the mirror and wondered, “Who am I now? Why did this diagnosis happen to me? When will this be over?
As reported on Pharma Phorum, Roivant Sciences and its subsidiary Priovant Therapeutics have received U.S. Food and Drug Administration (FDA) approval for Lisraya (brepocitinib), marking
As reported on Business Wire, AstraZeneca has finalized its previously announced licensing agreement with Dizal Pharmaceutical, gaining exclusive worldwide rights to develop and market ZEGFROVY
Treating acute ischemic strokes involves a precarious clinical balance: physicians must dissolve arterial clots to save brain tissue without triggering catastrophic intracranial hemorrhaging. To address
Editor’s Note: Patient Worthy is honored to share the following article, originally published by our friends at CURE SYNGAP1. To see the article in its
A Sustainable Biologic Solution Gains Major Insurance Coverage and Proves Superior to Synthetic Alternatives in Real-World Clinical Data In the world of advanced wound care
As reported on PharmaBiz, a new study published in Cell Stem Cell highlights a promising approach to cancer immunotherapy that combines stem cell technology with
They say sometimes you gotta laugh or you'll cry! Drop your best medical/patient related jokes in the comments 🤣🤣🤣
#laughthroughthetears #dadjokes #PatientWorthy
Follow along on our website and Patient Worthy social channels as we focus on multiple myeloma, sharing information about symptoms, diagnosis, treatment, ongoing research, and the experiences of those living with the condition.
Throughout the week, we’ll share articles, resources, and patient perspectives to help raise awareness and provide a deeper look at life with multiple myeloma.
Whether you’re living with multiple myeloma, supporting a loved one, or looking to learn more, we invite you to follow along, explore our latest stories, and help us continue bringing greater awareness to the multiple myeloma community. If you'd like to share your story, click here: ow.ly/eTB750ZIogY
#FocusOfTheWeek #MultipleMyeloma #MultipleMyelomaAwareness #PatientWorthy #PatientStories #CancerAwareness
Effective HAE management is about finding what works for you. From treatment plans to ongoing support, every step taken toward managing your condition can help create a stronger foundation for daily life.
Whether you're navigating HAE yourself, caring for a loved one, or looking to learn more about the condition, knowledge and community can make a meaningful difference. If you'd like to learn more about HAE or share your unique healthcare journey, visit PatientWorthy.com and help inspire others through the power of lived experience.
#HAE #HereditaryAngioedema #RareDiseaseAdvocacy #shareyourstory #PatientWorthy #RareDiseaseCommunity
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
